Our Brand Division
The Watson Brand division brings diversification to our business mix through a portfolio of patented and off-patented trademarked products. This business develops, manufactures and markets its products through two core areas: our Specialty Products product line includes urology and a number of other non-promoted products, and our Nephrology product line, which is primarily marketed to nephrologists and dialysis centers, features products for the treatment of iron deficiency anemia. The Watson Brand division is integral to our Company’s long-term strategy for “balanced” growth.
Highlights
- Focused on specialty physicians (urology and nephrology)
- 27 pharmaceutical product families in the portfolio
- Generated approximately $455 million in brand revenue during 2008
- Accounted for 18% of total 2008 annual revenue at Watson
Key Brands
| In Urology | In Nephrology |
|---|---|
|
RAPAFLO® (silodosin) capsules
A treatment for the signs and symptoms of benign prostatic hyperplasia |
FERRLECIT® (sodium ferric gluconate complex in sucrose injection) IV iron replacement therapy for certain patients with iron deficiency anemia |
|
GELNIQUE® (oxybutynin chloride) 10% gel
A treatment for overactive bladder symptoms |
INFeD® (iron dextran injection)
IV iron replacement therapy for certain patients with iron deficiency anemia |
|
TRELSTAR® LA / TRELSTAR® DEPOT (triptorelin pamoate for injectable suspension)
A treatment for advanced prostate cancer symptoms |
R&D Pipeline
| Indication/Therapeutic Target |
 |
 |
 |
 |
 |
 |
 |
|
|---|---|---|---|---|---|---|---|---|
|
TRELSTAR® (triptorelin pamoate for injectable suspension)
6-month formulation |
Advanced Prostate Cancer/Urology | U.S. |  |
|
|
|
||
|
Novel Oral Contraceptive
|
Prevention of Pregnancy | U.S. | |
|
|
|||
|
URACYST® (sterile sodium chondroitin sulfate)
|
Interstitial cystitis | U.S. | |
|
